Circulating lymphocyte subsets in different clinical situations after renal transplantation

Immunology

Volumn 136, Issue 2, 2012, Pages 198-207

  van de Berg, Pablo J E J ^a   Hoevenaars, Eveline C ^a   Yong, Si La ^a   van Donselaar van der Pant, Karlijn A M I ^a   van Tellingen, Anne ^a   Florquin, Sandrine ^a   van Lier, René A W ^a,b   Bemelman, Fréderike J ^a   ten Berge, Ineke J M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

Author keywords

Acute rejection; Chronic allograft dysfunction; Kidney transplantation; Lymphocytes; Subclinical rejection; T cell subsets

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; IMMUNOGLOBULIN D; INTERLEUKIN 7 RECEPTOR; TRANSCRIPTION FACTOR FOXP3;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; B LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTE SUBPOPULATION; MALE; MEMORY CELL; PERIPHERAL LYMPHOCYTE; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ADULT; AGED; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED;

EID: 84860249242     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/j.1365-2567.2012.03570.x     Document Type: Article

References (39)

1. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11:450-62.
2. Segev DL. Renal allograft survival: getting better all the time. Am J Transplant 2011; 11:422-3.
3. Brouard S, Renaudin K, Soulillou JP. Revisiting the natural history of IF/TA in renal transplantation. Am J Transplant 2011; 11:647-9.
4. Shapiro R. End-stage renal disease in 2010: innovative approaches to improve outcomes in transplantation. Nat Rev Nephrol 2011; 7:68-70.
5. Bromberg JS, Heeger PS, Li XC. Evolving paradigms that determine the fate of an allograft. Am J Transplant 2010; 10:1143-8.
6. Sawitzki B, Pascher A, Babel N, Reinke P, Volk HD. Can we use biomarkers and functional assays to implement personalized therapies in transplantation? Transplantation 2009; 87:1595-601.
7. Moreso F, Seron D, O'Valle F et al. Immunephenotype of glomerular and interstitial infiltrating cells in protocol renal allograft biopsies and histological diagnosis. Am J Transplant 2007; 7:2739-47.
8. Scherer A, Gwinner W, Mengel M et al. Transcriptome changes in renal allograft protocol biopsies at 3months precede the onset of interstitial fibrosis/tubular atrophy (IF/TA) at 6months. Nephrol Dial Transplant 2009; 24:2567-75.
9. high cell population in solid organ transplant recipients. J Exp Med 2007; 204:1533-41.
10. high activated T cells in kidney transplant recipients. Clin J Am Soc Nephrol 2011; 6:2025-33.
11. + T cells. Curr Opin Immunol 2008; 20:339-43.
12. Van de Berg PJ, van Stijn A, ten Berge IJ, van Lier RA. A fingerprint left by cytomegalovirus infection in the human T cell compartment. J Clin Virol 2008; 41:213-7.
13. + T-cell differentiation in response to viruses. Nat Rev Immunol 2003; 3:931-9.
14. Reinke P, Fietze E, Ode-Hakim S, Prösch S, Lippert J, Ewert R, Volk HD. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994; 344:1737-8.
15. + T cells. J Immunol 2006; 177:4998-5005.
16. +, cytomegalovirus-specific T cell subset after recovery of primary cytomegalovirus infection. J Immunol 2004; 173:134-41.
17. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78:242-9.
18. + T cells in healthy and immunosuppressed virus carriers. Blood 2001; 98:754-61.
19. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 1998; 187:875-83.
20. + T cell differentiation. J Clin Invest 2010; 120:4077-90.
21. Durkan AM, Alexander RT, Liu GY, Rui M, Femia G, Robinson LA. Expression and targeting of CX3CL1 (fractalkine) in renal tubular epithelial cells. J Am Soc Nephrol 2007; 18:74-83.
22. Matz M, Beyer J, Wunsch D et al. Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function. Kidney Int 2006; 69:1683-90.
23. Peng W, Chen J, Jiang Y et al. Urinary fractalkine is a marker of acute rejection. Kidney Int 2008; 74:1454-60.
24. + T reg cells. J Exp Med 2006; 203:1701-11.
25. Seddiki N, Santner-Nanan B, Martinson J et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203:1693-700.
26. + T cells with normal immuno-regulatory properties in long-term graft outcome. Transpl Int 2007; 20:845-55.
27. + T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006; 81:398-407.
28. neg invariant natural killer regulatory T cells in stable heart transplant recipients. Clin Exp Immunol 2011; 163:104-12.
29. + cells in renal allografts during acute rejection. Am J Transplant 2007; 7:914-22.
30. Yapici U, Bemelman FJ, Scheepstra CG et al. Intragraft FOXP3 protein or mRNA during acute renal allograft rejection correlates with inflammation, fibrosis, and poor renal outcome. Transplantation 2009; 87:1377-80.
31. high T cells as immune biomarker of renal function in transplant patients. Transplantation 2009; 88(3 Suppl):S85-93.
32. high T cells. Liver Transpl 2010; 16:49-55.
33. Fourtounas C, Dousdampanis P, Sakellaraki P, Rodi M, Georgakopoulos T, Vlachojannis JG, Mouzaki A. Different immunosuppressive combinations on T-cell regulation in renal transplant recipients. Am J Nephrol 2010; 32:1-9.
34. Nikolaeva N, Bemelman FJ, Yong SL, van Lier RA, ten Berge IJ. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation 2006; 81:445-54.
35. + regulatory T cells in renal transplant recipients. Transplantation 2006; 82:550-7.
36. Hester J, Mills N, Shankar S, Carvalho-Gaspar M, Friend P, Wood KJ. Th17 cells in alemtuzumab-treated patients: the effect of long-term maintenance immunosuppressive therapy. Transplantation 2011; 91:744-50.
37. Tsaur I, Gasser M, Aviles B et al. Donor antigen-specific regulatory T-cell function affects outcome in kidney transplant recipients. Kidney Int 2011; 79:1005-12.
38. Daniel V, Naujokat C, Sadeghi M, Renner FC, Weimer R, Opelz G. Association of high IFN-γ plasma levels with low B-cell counts in renal transplant recipients with stable long-term graft function. Clin Transplant 2010; 24:281-9.
39. Struijk GH, Minnee RC, Koch SD, Zwinderman AH, van Donselaar-van der Pant KA, Idu MM, ten Berge IJ, Bemelman FJ. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney Int 2010; 78:934-40.